Related Experiment Video
Updated: Aug 8, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Dendritic Cell Vaccines for Glioblastoma: A Systematic Review and Meta-Analysis Comparing New-Onset and Recurrent
Abdulsalam Mohammed Aleid1, Ibrahim Abdullah Houlbah2, Mohammed Yahya Abutaleb3
1Department of Surgery, Medical College, King Faisal University, Ahsa, Saudi Arabia.
Anti-Cancer Agents in Medicinal Chemistry
|August 7, 2026
Summary
Dendritic cell (DC)-based immunotherapy improves survival in glioblastoma (GBM) patients. While more impactful in recurrent GBM, overall survival benefits were greater in newly diagnosed cases, highlighting its potential in GBM treatment.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Research
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis and high recurrence rates.
- Current treatments offer limited survival benefits, necessitating novel therapeutic strategies.
- Dendritic cell (DC)-based immunotherapies show promise for enhancing anti-tumor immune responses in GBM.
Purpose of the Study:
- To compare the effectiveness of DC-based immunotherapy in improving survival outcomes for patients with newly diagnosed or recurrent GBM.
- To evaluate the impact of DC vaccines on overall survival (OS) and progression-free survival (PFS) in GBM.
- To synthesize evidence on DC immunotherapy efficacy in GBM through a meta-analysis.
Main Methods:
- A systematic literature search was conducted across four major databases up to March 2024.
- Included studies evaluated DC vaccines for newly diagnosed and recurrent GBM.
- Study quality was assessed using the Cochrane risk-of-bias tool, and data were analyzed using Review Manager (RevMan) 5.4.
Main Results:
- Three studies with 355 patients were included in the meta-analysis.
- DC-based immunotherapy demonstrated a greater impact on recurrent GBM but favored newly diagnosed cases for overall survival (HR = 0.62, p = 0.002).
- Progression-free survival also favored newly diagnosed cases (HR = 0.56, p = 0.05), with no significant heterogeneity observed in either outcome.
Conclusions:
- Dendritic cell-based immunotherapy can enhance survival outcomes in glioblastoma patients.
- The findings suggest DC immunotherapy is more effective in newly diagnosed GBM compared to recurrent cases.
- Further research may elucidate optimal strategies for utilizing DC immunotherapy in different GBM settings.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.